Quantifying the risk of pandemic influenza in pregnancy and indigenous people in Australia in 2009.

Kelly H, Mercer G, Cheng A.
Euro Surveill. 2009 Dec 17;14(50). pii: 19441.

WHO criteria for measles elimination: a critique with reference to criteria for polio elimination.

Kelly H, Riddell M, Heywood A, Lambert S.
Euro Surveill. 2009 Dec 17;14(50). pii: 19445. Review.

High proportion of influenza B characterises the 2008 influenza season in Victoria.

Grant KA, Carville K, Fielding JE, Barr IG, Riddell MA, Tran T, Kelly HA.
Commun Dis Intell. 2009 Sep;33(3):328-36.

Annual report of the Australian National Poliovirus Reference Laboratory, 2008.

Roberts JA, Grant KA, Yoon YK, Polychronopoulos S, Ibrahim A, Thorley BR.
Commun Dis Intell. 2009 Sep;33(3):291-7.

Large trials confirm immunogenicity of H1N1 vaccines.

Kelly H, Barr I.
Lancet. 2010 Jan 2;375(9708):6-9. Epub 2009 Dec 15. No abstract available.

Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses.

Revill P, Yuen L, Walsh R, Perrault M, Locarnini S, Kramvis A.
J Med Virol. 2010 Jan;82(1):104-15.

Does RNA interference provide new hope for control of chronic hepatitis B infection?

Wilson R, Purcell D, Netter HJ, Revill PA.
Antivir Ther. 2009;14(7):879-89. Review.

Prevalence of transmitted HIV drug resistance since the availability of highly active antiretroviral therapy.

Russell JS, Chibo D, Kaye MB, Gooey ML, Carolan LA, Papadakis A, Nicholls JA, Birch CJ.
Commun Dis Intell. 2009 Jun;33(2):216-20.

Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro.

Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S.
Antivir Ther. 2009;14(6):797-808.

Multidrug-resistant tuberculosis in Victoria: a 10-year review.

Lavender CJ, Brown LK, Johnson PD.
Med J Aust. 2009 Sep 21;191(6):315-8.

The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B.

Nguyen T, Desmond P, Locarnini S.
Hepatol Int. 2009 Sep 18. [Epub ahead of print]

Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination.

Kelly H, Grant K.
Euro Surveill. 2009 Aug 6;14(31). pii: 19288.

Hepatitis B: the case for combination therapy.

Bowden S, Shaw T.
Curr Opin Investig Drugs. 2009 Aug;10(8):795-803. Review.

Epidemiological characteristics of pandemic influenza H1N1 2009 and seasonal influenza infection.

Kelly HA, Grant KA, Williams S, Fielding J, Smith D.
Med J Aust. 2009 Aug 3;191(3):146-9.

H1N1 swine origin influenza infection in the United States and Europe in 2009 may be similar to H1N1 seasonal influenza infection in two Australian states in 2007 and 2008.

Kelly H, Grant K, Williams S, Smith D.
Influenza Other Respi Viruses. 2009 Jul;3(4):183-8.

Molecular and epidemiological features of GIIb norovirus outbreaks in Victoria, Australia, 2002-2005.

Bruggink LD, Marshall JA.
J Med Virol. 2009 Sep;81(9):1652-60.

Comparison of Bayesian and maximum-likelihood phylogenetic approaches in two legal cases involving accusations of transmission of HIV.

Kaye M, Chibo D, Birch C.
AIDS Res Hum Retroviruses. 2009 Aug;25(8):741-8.

Identification of a novel codon in the norovirus GII.4 polymerase region which acts as a marker of major GII.4 norovirus epidemics.

Bruggink LD, Marshall JA.
Infect Genet Evol. 2009 Jul;9(4):653-5. Epub 2009 Jan 19.

Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?

Warner N, Locarnini S.
Antivir Ther. 2009;14(2):139-42. No abstract available.

Estimation of influenza vaccine effectiveness from routine surveillance data.

Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I.
PLoS One. 2009;4(3):e5079. Epub 2009 Mar 31.

Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.

Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK.
J Infect. 2009 May;58(5):375-82. Epub 2009 Mar 27.

Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model.

Thorley B, Kelly H, Nishimura Y, Yoon YK, Brussen KA, Roberts J, Shimizu H.
J Clin Virol. 2009 Apr;44(4):268-71. Epub 2009 Mar 9.